tirzepatide renal impairment (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Tirzepatide and Kidney Health: Safety

High-fat A2 dairy will likely come back

See our side effects page to learn more about tirzepatide side effects

This blog post delves into the latest scientific findings to provide a comprehensive understanding of semaglutide's role in weight management

The GLP-1R/GIPR dual-agonist tirzepatide has demonstrated a remarkable 23% body weight reduction in individuals with obesity over 72 weeks, eclipsing the average result achieved by certain bariatric surgery [78]

KKF, a source for health policy research, polling and news, in May 2024 released a poll that found 12% of adults said they had taken a GLP-1 agonist, with 6% saying they currently take the drug